EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 / No 4 (Avril 2005) Med Sci (Paris), 21 4 (2005) 434-442 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Number 4, Avril 2005
Page(s) 434 - 442
Section Forum
DOI https://doi.org/10.1051/medsci/2005214434
Published online 15 April 2005
  1. Hardy-Baylé MC. Schizophrénie : symptômes et diagnostic. Med Ther 1996; 2 : 613–20. [Google Scholar]
  2. Clervoy P, Corcos M. Épidemiologie et histoire naturelle de la schizophrénie. Rev Prat 2002; 52 : 1177–82. [Google Scholar]
  3. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158 : 176–84. [Google Scholar]
  4. Meltzer HY. Cognitive factors in schizophrenia : causes, impact, and treatment. CNS Spectr 2004; 9 : 15–24. [Google Scholar]
  5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60 : 553–64. [Google Scholar]
  6. Houy-Durand E, Thibaut F. Traitements des schizophrénies. Rev Prat 2002; 52 : 1213–20. [Google Scholar]
  7. Krebs MO. Hypothèses génétiques de la schizophrénie. Rev Prat 2002; 52 : 1208–11. [Google Scholar]
  8. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology : on the matter of their convergence. Mol Psychiatry 2005; 10 : 40–68. [Google Scholar]
  9. Niznikiewicz MA, Kubicki M, Shenton ME. Recent structural and functional imaging findings in schizophrenia. Curr Opin Psychiatry 2003; 16 : 123–47. [Google Scholar]
  10. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia : insights from brain imaging studies. Eur Psychiatry 2005; 20 : 15–27. [Google Scholar]
  11. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol 2003; 27 : 1071–9. [Google Scholar]
  12. Millan MJ. NMDA receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia : a critical review. Curr Drug Targets 2002; 1 : 191–213. [Google Scholar]
  13. Dean B, Scarr E. Antipsychotic drugs : evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets 2004; 3 : 217–25. [Google Scholar]
  14. Millan MJ, Brocco M, Gobert A, et al. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine : importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999; 11 : 4419–32. [Google Scholar]
  15. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors : their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 : 1159–72. [Google Scholar]
  16. Meltzer HY, Arvanitis L, Bauer D, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161 : 975–84. [Google Scholar]
  17. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 : 1145–58. [Google Scholar]
  18. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 : 1081–90. [Google Scholar]
  19. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90 : 231–59. [Google Scholar]
  20. McGowan S, Lawrence AD, Sales T, et al. Presynaptic dopaminergic dysfunction in schizophrenia : a positron emission tomographic 18F fluorodopa study. Arch Gen Psychiatry 2004; 61 : 134–42. [Google Scholar]
  21. Tsapakis EM, Guillin O, Murray RM. Does dopamine sensitisation underlie the association between schizophrenia and drug abuse ? Curr Opin Psychiatry 2003; 16 : S45–52. [Google Scholar]
  22. Richtand NM, Woods SC, Berger P, Strakowski SM. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 2001; 25 : 427–43. [Google Scholar]
  23. Hill K, Mann L, Laws KR, et al. Hypofrontality in schizophrenia : a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004; 110 : 243–56. [Google Scholar]
  24. Millan MJ, Seguin L, Gobert A, et al. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity : a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 2004; 174 : 341–57. [Google Scholar]
  25. Holmes A, Lachowicz JE, Sibley DR. Phenotypic analysis of dopamine receptor knockout mice : recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology 2004; 47 : 1117–34. [Google Scholar]
  26. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signalling. J Recept Signal Transduct Res 2004; 24 : 165–205. [Google Scholar]
  27. Steele TD, Hodges DB, Levesque TR, Locke KW. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmacol Biochem Behav 1997; 58 : 477–83. [Google Scholar]
  28. Swainston Harrison T, Perry CM. Aripiprazole : a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 : 1715–36. [Google Scholar]
  29. Millan MJ, Dekeyne A, Rivet JM, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors. II. Functional and behavioural profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293 : 1063–73. [Google Scholar]
  30. Silverdale MA, Nicholson SL, Ravenscroft P, et al. Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004; 188 : 128–38. [Google Scholar]
  31. Millan MJ. The role of monoamines in the actions of established and « novel » antidepressant agents : a critical review. Eur J Pharmacol 2004; 500 : 371–84. [Google Scholar]
  32. Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000; 294 : 1154–65. [Google Scholar]
  33. Jongen-Relo AL, Drescher KU, Teschendorf HJ, et al. Effects of dopamine D3 receptor antagonists and antipsychotic drugs on the disruption of huddling behavior by dopamine agonists. Am Soc Neurosci 2004; 29 : 350.2 (abstract). [Google Scholar]
  34. Robertson GS, Lee CJ, Sridhar K, et al. Clozapine-, but not haloperidol-, induced increases in FosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004; 20 : 3189–94. [Google Scholar]
  35. Glickstein SB, Desteno DA, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2004 (10 novembre, online). [Google Scholar]
  36. Dekeyne A, Di Cara B, Gobert A, Millan MJ. Blockade of dopamine D3 receptors enhances frontocortical cholinergic transmission and cognitive function in rats. Am Soc Neurosci 2004; 29 : 776.4 (abstract). [Google Scholar]
  37. Lacroix LP, Hows ME, Shah AJ, et al. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003; 28 : 839–49. [Google Scholar]
  38. Leriche L, Diaz J, Sokoloff P. Dopamine and glutamate dysfunctions in schizophrenia : role of the dopamine D3 receptor. Neurotox Res 2004; 6 : 63–72. [Google Scholar]
  39. Gurevich EV, Bordelon Y, Shapiro RM, et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997; 54 : 225–32. [Google Scholar]
  40. Dubertret C, Gorwood P, Ades J, et al. Meta-analysis of DRD3 and schizophrenia. Am J Med Genet 1998; 81 : 318–22. [Google Scholar]
  41. Jonsson EG, Flyckt L, Burgert E, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia : association study and meta-analysis. Psychiatr Genet 2003; 13 : 1–12. [Google Scholar]
  42. Luedtke RR, Mach RH. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharmacol Design 2003; 9 : 643–71. [Google Scholar]
  43. Dubuffet T, Newman-Tancredi A, Cussac D, et al. Novel benzopyrano [3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. Bioorg Med Chem Lett 1999; 9 : 2059–64. [Google Scholar]
  44. Brocco M, Gobert A, Dekeyne A, et al. S33138, a novel and preferential antagonist at dopamine D3 receptors : functional profile in rodent models of the control of negative-cognitive symptoms of schizophrenia. Int J Neuropsychopharmacol 2004; 7 (suppl 1) : S265 (abstract). [Google Scholar]
  45. Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia : NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Res 2004; 72 : 5–9. [Google Scholar]
  46. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347 : 146–51. [Google Scholar]
  47. Xi ZX, Gilbert J, Campos AC, et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 2004; 176 : 57–65. [Google Scholar]
  48. Le Foll B, Francès H, Diaz J, et al. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002; 15 : 2016–26. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.